News

Targeting miRNA-214 May Decrease Cell Proliferation in PAH, Study Reports

A microRNA, called miR-214, promotes excessive cellular proliferation in pulmonary arterial hypertension (PAH), and decreasing its expression may significantly impair phenotype changes in the lung vasculature in PAH, researcher report.The study, “MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension,” was published…

Galectin to Present Data on Potential PAH Treatment, a Galectin-3 Inhibitor, at ATS 2016

Galectin Therapeutics, Inc., will present an abstract, a collaboration with researchers at Augusta University titled “Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension,” at the 2016 International Conference of the American Thoracic Society (ATS) being held May 13–18 in San Francisco. The study, undertaken in the labs of Drs. Scott Barman and…

Insmed to Present Latest Data on PAH and Other Potential Pulmonary Treatments at ATS 2016

Insmed, Inc., recently announced that three abstracts related to Arikayce, its drug candidate to treat nontuberculous mycobacteria (NTM) lung disease, and one related to its treprostinil prodrug, will be presented at the American Thoracic Society (ATS) 2016 International Conference taking place in San Francisco on May 13–18. The presentations will cover clinical trial findings…

AVEO Files New Patent Applications for AV-353, a Notch 3 Inhibitor Showing Promise as PAH Therapy

AVEO Oncology announced that it has filed provisional patent applications covering “composition of matter” claims for its Notch 3-specific inhibitory antibody, AV-353. The latest filings are the company’s second concerning its Notch 3 antibody program and AV-353. The Notch signaling pathway is involved in multiple cell fate decisions throughout human life,…

Pulmonary Vasodilator Monotherapy in PAH Improves Exercise Capacity, Study Reports

Monotherapy given to patients with congenital heart defects associated with pulmonary arterial hypertension, or PAH-CHD, improved their exercise capacity more than a combined therapy, researchers report. The study, “Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis,” was published in the journal Open…